Argenx halts UNITY study. Argenx stock trades 1.18 percent higher

Published on 10/12/2026 at 09:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FB102 met its primary endpoint at p=0.0176 on October 8, 2026. Argenx stock costs EUR 744.70 versus EUR 736.00.

Key points in brief

Argenx discontinued its Phase 3 UNITY study in Sjogren's disease after an interim analysis found the trial futile.
FB102 met its Phase 2 celiac disease primary endpoint with p=0.0176 on October 8, 2026.
Argenx stock traded at EUR 744.70 on October 12, 2026, up 1.18 percent versus the Xetra close of EUR 736.00 on October 9, 2026.
Second-quarter 2026 revenue reached USD 1.54 billion and diluted earnings per share came to USD 7.32.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund — Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

At EUR 744.70, Argenx stock was 1.18 percent higher on October 12, 2026, while the company dealt with a setback in its Phase 3 UNITY study. FinanzNachrichten reported on October 8, 2026, that Argenx would discontinue the study after an interim analysis found that it was unable to meet its primary endpoint.

Three events define the reset

On July 21, 2026, Argenx reported second-quarter revenue of USD 1.54 billion and diluted earnings per share of USD 7.32, compared with consensus revenue of USD 1.45 billion and consensus earnings per share of USD 5.86, according to MarketBeat. On October 8, 2026, Argenx reported that FB102 met its Phase 2 primary endpoint in celiac disease at p=0.0176, per FinanzNachrichten. On the same date, the company discontinued UNITY, a Phase 3 study designed to measure disease activity at Week 48.

What offsets the trial setback?

The FB102 result gives Argenx a second clinical development angle after the UNITY decision. The Phase 2 study enrolled 126 patients, and the company plans to advance FB102 into Phase 3 development, according to FinanzNachrichten. The contrast is material: the lead clinical program lost one expansion opportunity, while FB102 produced a statistically significant Phase 2 signal.

The earnings backdrop remains substantial. Second-quarter revenue of USD 1.54 billion exceeded the USD 1.45 billion consensus by USD 90.00 million, while diluted earnings per share of USD 7.32 exceeded the USD 5.86 consensus by USD 1.46. That operating scale gives the pipeline outcome more weight than a single early-stage readout.

Argenx stock stays above the Xetra close

Argenx stock was trading at EUR 744.70 at Lang & Schwarz on October 12, 2026 at 9:38 a.m. CEST, up 1.18 percent versus the Xetra close of EUR 736.00 on October 9, 2026. The company also trades on Euronext Brussels and Nasdaq, while the latest primary-market quote available from October 9, 2026 was USD 825.03 on Nasdaq after the regular session.

The further course of trading is shown by the continuously updated real-time quote of Argenx stock.